Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of North Carolina, Chapel Hill
With
National Institute of Allergy and Infectious Diseases (NIAID)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HIV positive patients
Able to provide written informed consent
Able to comply with their treatment regimen and study procedures
Currently receiving either efavirenz/tenofovir/emtricitabine or atazanavir/ritonavir/tenofovir/emtricitabine as treatment for their HIV infection. Subjects must have been on the regimen for at least 2 weeks
All women of reproductive potential must have a negative urine pregnancy test
If participating in sexual activity that could lead to pregnancy, study participant must use at least one reliable method of contraception.
You may not be if
Displaying the fraility phenotype (Group A only)
Receiving an interacting medication
Having missed \>3 doses of study medication in the past 30 days
Patients who will not likely remain on the study regimen during the course of study participation.
Anemia (hemoglobin \<10 g/dL)
Abnormal screening laboratory findings
Pregnancy
Breastfeeding
Any condition that may interfere with follow-up or the ability to take the study medication appropriately.
Any clinically significant surgical alterations of the alimentary track, that in the opinion of the investigators, alters the absorption pharmacokinetics of the drugs of interest.
